Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Adebrelimab + FOLFOX + Bevacizumab for Advanced Unresectable HCC
ChiCTR2600119521Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Objective response rate (ORR). Started Feb 2026; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600119521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119521.